NASDAQ:MDWD MediWound (MDWD) Stock Forecast, Price & News $10.87 +1.67 (+18.15%) (As of 09/28/2023 ET) Add Compare Share Share Today's Range$8.82▼$10.9950-Day Range$7.28▼$10.8752-Week Range$7.10▼$14.58Volume95,203 shsAverage Volume33,758 shsMarket Capitalization$100.11 millionP/E RatioN/ADividend YieldN/APrice Target$29.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media MediWound MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside166.8% Upside$29.00 Price TargetShort InterestHealthy0.78% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.55Based on 10 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.52) to ($1.86) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.78 out of 5 starsMedical Sector816th out of 970 stocksMedicinals & Botanicals Industry8th out of 12 stocks 3.5 Analyst's Opinion Consensus RatingMediWound has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $29.00, MediWound has a forecasted upside of 166.8% from its current price of $10.87.Amount of Analyst CoverageMediWound has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.78% of the float of MediWound has been sold short.Short Interest Ratio / Days to CoverMediWound has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MediWound has recently increased by 23.60%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMediWound does not currently pay a dividend.Dividend GrowthMediWound does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MDWD. Previous Next 2.5 News and Social Media Coverage News SentimentMediWound has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for MediWound this week, compared to 1 article on an average week.MarketBeat Follows3 people have added MediWound to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MediWound insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.20% of the stock of MediWound is held by insiders.Percentage Held by InstitutionsOnly 22.32% of the stock of MediWound is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for MediWound are expected to decrease in the coming year, from ($1.52) to ($1.86) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MediWound is -4.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MediWound is -4.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMediWound has a P/B Ratio of 7.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About MediWound (NASDAQ:MDWD) StockMediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.Read More MDWD Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MDWD Stock News HeadlinesSeptember 27, 2023 | americanbankingnews.comStockNews.com Upgrades MediWound (NASDAQ:MDWD) to "Hold"September 26, 2023 | finance.yahoo.comMediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. ArmySeptember 29, 2023 | Weiss Ratings (Ad)The Make Your Money Safe Again SolutionJust a few weeks ago, without ever getting your permission... Dozens and dozens of major banks across America made a sweeping change to how they handle your money. This danger creates a weakness in your account.September 25, 2023 | americanbankingnews.comFY2023 EPS Estimates for MediWound Ltd. Raised by HC Wainwright (NASDAQ:MDWD)September 23, 2023 | americanbankingnews.comMediWound (NASDAQ:MDWD) PT Raised to $26.00 at HC WainwrightSeptember 22, 2023 | markets.businessinsider.comMaxim Group Sticks to Their Buy Rating for Mediwound (MDWD)September 21, 2023 | msn.comMediWound burn therapy NexoBrid launched in USSeptember 21, 2023 | markets.businessinsider.comHC Wainwright & Co. Maintains Buy Rating for MediWound: Here's What You Need To KnowSeptember 29, 2023 | Chaikin Analytics (Ad)His system isolated NVIDIA - Here's His Next Buy.Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.September 21, 2023 | markets.businessinsider.comMediWound Announces Full Commercial Launch Of NexoBrid - Quick FactsSeptember 21, 2023 | finance.yahoo.comMediWound Announces U.S. Commercial Availability of NexoBrid® for the Treatment of Severe Thermal Burns in AdultsSeptember 19, 2023 | americanbankingnews.comMediWound (NASDAQ:MDWD) Cut to "Sell" at StockNews.comSeptember 11, 2023 | markets.businessinsider.comMediWound’s NexoBrid® Highlighted in 20 Oral and Poster Presentations at the 20th European Burns Association CongressSeptember 5, 2023 | finance.yahoo.comMediWound to Participate in Fireside Chat at H.C. Wainwright 25th Annual Global Investment ConferenceAugust 25, 2023 | finance.yahoo.comHere's Why We're Not Too Worried About MediWound's (NASDAQ:MDWD) Cash Burn SituationAugust 18, 2023 | markets.businessinsider.comMaxim Group Sticks to Its Buy Rating for Mediwound (MDWD)August 17, 2023 | msn.comOppenheimer Maintains MediWound (MDWD) Outperform RecommendationAugust 17, 2023 | markets.businessinsider.comWhat 4 Analyst Ratings Have To Say About MediWoundAugust 16, 2023 | finanznachrichten.deMediWound Ltd.: MediWound Announces Collaboration with Mölnlycke on EscharEx Phase III StudyAugust 15, 2023 | finance.yahoo.comMediWound (MDWD) Q2 Earnings and Revenues Beat EstimatesAugust 15, 2023 | finance.yahoo.comMediWound Announces Collaboration with Mölnlycke on EscharEx® Phase III StudyAugust 15, 2023 | finance.yahoo.comMediWound Reports Second Quarter 2023 Financial Results and Provides Company UpdateAugust 14, 2023 | seekingalpha.comMediWound Q2 2023 Earnings PreviewAugust 7, 2023 | finance.yahoo.comMediWound to Report Second Quarter 2023 Financial ResultsAugust 1, 2023 | finance.yahoo.comMediWound Announces Commercial Launch of NexoBrid® in JapanJuly 10, 2023 | finance.yahoo.comMediWound Announces Positive Results in Its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell CarcinomaJuly 3, 2023 | markets.businessinsider.comMediWound Gets Scientific Advice From EMA Supporting Phase III Development Plan For EscharExSee More Headlines Receive MDWD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MediWound and its competitors with MarketBeat's FREE daily newsletter. Email Address MDWD Company Calendar Last Earnings8/15/2023Today9/29/2023Next Earnings (Estimated)11/21/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Medicinals & botanicals Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MDWD CUSIPN/A CIK1593984 Webwww.mediwound.com Phone972779714100Fax972-77-971-4111Employees83Year Founded2001Price Target and Rating Average Stock Price Forecast$29.00 High Stock Price Forecast$36.00 Low Stock Price Forecast$25.00 Forecasted Upside/Downside+166.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($2.4297) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,600,000.00 Net Margins-55.53% Pretax Margin-55.19% Return on Equity-71.45% Return on Assets-27.28% Debt Debt-to-Equity RatioN/A Current Ratio6.99 Quick Ratio6.61 Sales & Book Value Annual Sales$26.50 million Price / Sales3.78 Cash FlowN/A Price / Cash FlowN/A Book Value$1.51 per share Price / Book7.20Miscellaneous Outstanding Shares9,210,000Free Float8,359,000Market Cap$100.11 million OptionableNot Optionable Beta1.09 Social Links Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Ofer Gonen B.Sc. (Age 50)Chief Exec. Officer Comp: $485kDr. Lior Rosenberg M.D. (Age 77)Co-Founder Comp: $727kDr. Ety Klinger MBA (Age 61)Ph.D., Chief R&D Officer Comp: $393kMs. Hani LuxenburgChief Financial OfficerMr. Tzvi Palash B.Sc. (Age 66)M.Sc., Chief Operating Officer Mr. Yaron Meyer Adv. (Age 44)Exec. VP, Gen. Counsel & Corp. Sec. Mr. Barry J. Wolfenson (Age 56)Exec. VP of Strategy & Corp. Devel. Dr. Robert J. Snyder CWS (Age 73)D.P.M., F.A.C.F.A.S., FFPM, M.B.A., M.Sc., Chief Medical Officer More ExecutivesKey CompetitorsFitLife BrandsNASDAQ:FTLFBright GreenNASDAQ:BGXXChromaDexNASDAQ:CDXCNatural Alternatives InternationalNASDAQ:NAIIMannatechNASDAQ:MTEXView All CompetitorsInstitutional OwnershipWells Fargo & Company MNBought 15,535 shares on 8/15/2023Ownership: 1.224%Renaissance Technologies LLCSold 1,200 shares on 8/11/2023Ownership: 0.604%BlackRock Inc.Bought 8,392 shares on 8/11/2023Ownership: 0.166%Sargent Investment Group LLCBought 2,389 shares on 7/31/2023Ownership: 1.120%Cowen Prime Advisors LLCBought 10,639 shares on 7/31/2023Ownership: 0.363%View All Institutional Transactions MDWD Stock - Frequently Asked Questions Should I buy or sell MediWound stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MediWound in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MDWD shares. View MDWD analyst ratings or view top-rated stocks. What is MediWound's stock price forecast for 2023? 4 analysts have issued 12 month target prices for MediWound's stock. Their MDWD share price forecasts range from $25.00 to $36.00. On average, they anticipate the company's stock price to reach $29.00 in the next twelve months. This suggests a possible upside of 166.8% from the stock's current price. View analysts price targets for MDWD or view top-rated stocks among Wall Street analysts. How have MDWD shares performed in 2023? MediWound's stock was trading at $13.49 at the beginning of the year. Since then, MDWD shares have decreased by 19.4% and is now trading at $10.87. View the best growth stocks for 2023 here. Are investors shorting MediWound? MediWound saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 50,800 shares, an increase of 23.6% from the August 31st total of 41,100 shares. Based on an average trading volume of 17,900 shares, the short-interest ratio is presently 2.8 days. Approximately 0.8% of the shares of the company are sold short. View MediWound's Short Interest. When is MediWound's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 21st 2023. View our MDWD earnings forecast. How were MediWound's earnings last quarter? MediWound Ltd. (NASDAQ:MDWD) announced its earnings results on Tuesday, August, 15th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating the consensus estimate of ($0.41) by $0.51. The biopharmaceutical company earned $4.77 million during the quarter, compared to the consensus estimate of $4.19 million. MediWound had a negative trailing twelve-month return on equity of 71.45% and a negative net margin of 55.53%. When did MediWound's stock split? MediWound's stock reverse split before market open on Tuesday, December 20th 2022. The 1-7 reverse split was announced on Tuesday, December 20th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, December 20th 2022. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split. What other stocks do shareholders of MediWound own? Based on aggregate information from My MarketBeat watchlists, some companies that other MediWound investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), Blackstone (BX), Dynavax Technologies (DVAX), Geron (GERN), Idera Pharmaceuticals (IDRA), Mastercard (MA), SCYNEXIS (SCYX), Vascular Biogenics (VBLT) and Wells Fargo & Company (WFC). What is MediWound's stock symbol? MediWound trades on the NASDAQ under the ticker symbol "MDWD." How do I buy shares of MediWound? Shares of MDWD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is MediWound's stock price today? One share of MDWD stock can currently be purchased for approximately $10.87. How much money does MediWound make? MediWound (NASDAQ:MDWD) has a market capitalization of $100.11 million and generates $26.50 million in revenue each year. The biopharmaceutical company earns $-19,600,000.00 in net income (profit) each year or ($2.4297) on an earnings per share basis. How can I contact MediWound? MediWound's mailing address is 42 HAYARKON STREET, YAVNE L3, 8122745. The official website for the company is www.mediwound.com. The biopharmaceutical company can be reached via phone at 972779714100, via email at afields@lhai.com, or via fax at 972-77-971-4111. This page (NASDAQ:MDWD) was last updated on 9/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MediWound Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.